Studies classified under remyelination or regeneration, including preclinical and human research. Each record shows what its evidence can and cannot establish.
This hub updates as matching research records are published. AI-generated summaries are labelled when they have not yet been reviewed by a person.
AI
AI CuratorAI-generated
Research summary ·
AI summary · not yet reviewedAnimal studyPreclinicalPeer review unconfirmed
Research on leukotriene inhibitors in animal models showed that blocking certain pathways reduced symptoms of neuroinflammation and demyelination. Specifically, five studies indicated that inhibiting leukotriene B4 or its receptors helped lessen clinical severity in models of experimental autoimmune encephalomyelitis and cuprizone-induced demyelination.
What this does not proveThe results are based on animal studies and do not establish clinical efficacy in humans. More rigorous clinical trials are necessary to determine any actual benefits for MS patients.
Research indicates that specialized pro-resolving mediators (SPMs), such as resolvins, lipoxins, and maresins, can reduce neuroinflammation, prevent demyelination, and restore immune balance. Human studies show systemic deficiencies in lipid resolution pathways with increased pro-inflammatory eicosanoids.
What this does not proveKey questions remain about the causes of resolution failure, its varying dynamics at different disease stages, and the applicability of SPM interventions in human patients.
Research summaries are for information, not medical advice. Always consult your MS team before changing treatment.
Help us understand how PulseMS is used
With your permission, Google Analytics uses cookies to measure visits and interactions with research. It does not receive your email, account details or community posts. You can change your choice in the footer. Privacy details